Latest News and Press Releases

GAITHERSBURG, Md., Jan. 09, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation...

IND clearance enables commencement of clinical trial to evaluate NEXI-002 in Multiple Myeloma patients who have failed >3 previous lines of therapyFDA action represents the Company’s second IND...

GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune Modulation...

GAITHERSBURG, Md., Dec. 02, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical stage immunotherapy company developing novel T cell therapies, announced that Scott Carmer, Neximmune’s Chief Executive...

IND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients with relapsed disease after allogeneic stem cell transplantIND clearance validates Company’s Artificial...

GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Scott Carmer, NexImmune’s Chief Executive...

GAITHERSBURG, Md. and NORWALK, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- NexImmune and the Multiple Myeloma Research Foundation (MMRF) have entered into a partnership to advance a promising new...

GAITHERSBURG, Md., April 05, 2019 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that Scott Carmer, Neximmune’s Chief Executive...

GAITHERSBURG, Md., Dec. 11, 2018 (GLOBE NEWSWIRE) -- NexImmune, an emerging leader in the field of antigen-directed immunotherapy, today announced that the United States Patent and Trademark Office...

Naimish Pandya, MD assumes role of VP & Head, Clinical DevelopmentAlex Matschiner, MS ChE assumes role of VP, Protein Process Development GAITHERSBURG, Md., Dec. 04, 2018 (GLOBE NEWSWIRE) --...